Physician profile
Eric N Bravin
NPI 1053375279
$1,993.81
in general payments reported to CMS, 2019-2025
17 companies · $30.87 in 2025
The $30.87 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $80.00 · 2021: $261 · 2022: $266 · 2023: $165 · 2024: $678 · 2025: $30.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $325 · Education: $22.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $325.43 |
| Education | $22.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.89 | 2019-2024 | Imfinzi |
| Genzyme Corporation | $349.85 | 2019-2024 | |
| Lilly USA, LLC | $315.65 | 2019-2023 | Verzenio |
| Amgen INC. | $125.00 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $125.00 | 2019 | |
| Exelixis INC. | $92.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $62.12 | 2020-2022 | |
| Tg Therapeutics, INC. | $57.26 | 2021 | |
| Daiichi Sankyo INC. | $54.98 | 2022-2024 | Enhertu |
| Janssen Biotech, INC. | $31.34 | 2019-2020 | |
| Emd Serono, INC. | $30.87 | 2025 | |
| Seagen INC. | $23.29 | 2020 | |
| Apellis Pharmaceuticals, INC. | $22.88 | 2023 | Empaveli |
| Coherus Oncology, INC. | $21.15 | 2024 | |
| Genentech USA, INC. | $16.93 | 2023 | Kadcyla, Phesgo, Perjeta |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bravin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.